Skip to main content

Non-Bleeding Peptic Ulcers

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Medica Corp
Medica CorpMA - Bedford
1 program
1
OmeprazolePhase 3Small Molecule
Dexa Medica
Dexa MedicaIndonesia - Tangerang
1 program
1
OmeprazolePhase 3Small Molecule1 trial
Active Trials
NCT02262169Terminated32Est. Mar 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Dexa MedicaOmeprazole

Clinical Trials (1)

Total enrollment: 32 patients across 1 trials

DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers

Start: Oct 2014Est. completion: Mar 201932 patients
Phase 3Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.